首页> 外文期刊>Oncogenesis. >Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells
【24h】

Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells

机译:AKT /细胞周期蛋白D1 / Cdk4生存信号通路在抗放射癌干细胞中的激活

获取原文
       

摘要

Radioresistance, which is a major cause of failure of radiotherapy (RT), is proposed as one of the intrinsic characteristics of cancer stem cells (CSCs) whose unique DNA damage response (DDR), efficient DNA repair and resistance to apoptosis are thought to confer the phenotype. We have isolated surviving CSCs by exposure to long-term fractionated radiation for 82 days from HepG2 and A172 cells (82FR-31NR cells). 82FR-31NR cells exhibited CSC properties, such as high expression of CSC marker CD133 and the ABC transporters (MDR1 and BCRP1), and high tumorigenic potential after transplantation into nude mice. The advantage of our isolated CSCs is that they can proliferate in as the same growth medium as that of parental cells without loss of CSC properties. Therefore, we can analyze DDR of non-stem cells and CSCs without any influences caused by different culture conditions. 82FR-31NR cells showed efficient DNA repair of radiation-induced DNA damage and radioresistance with activation of the AKT/cyclin D1 survival signaling pathway. In contrast, DNA damage persisted for a long time after irradiation in parental cells compared with isolated CSCs. Persisted DNA damage induced apoptosis in parental cells without activation of the AKT/cyclin D1 pathway. Therefore, inhibition of the AKT/cyclin D1 pathway by an AKT inhibitor, API-2, or cyclin D1 siRNA resulted in a loss of efficient DNA repair and radiosensitization of 82FR-31NR cells. Furthermore, knockdown of Cdk4 by its siRNA or a Cdk4 inhibitor was sufficient to suppress radioresistance of CSCs. In this study, we present a newly discovered DDR regarding the AKT/cyclin D1/Cdk4 pathway in response to radiation in CSCs. Combination of fractionated RT and reagents targeting the AKT/cyclin D1/Cdk4 pathway to eradicate CSCs would be effective therapeutic modality.. ? 2012 Macmillan Publishers Limited
机译:放射抵抗是导致放射治疗(RT)失败的主要原因,被认为是癌症干细胞(CSC)的固有特征之一,其被认为具有独特的DNA损伤反应(DDR),有效的DNA修复和抗凋亡能力表型。我们已经通过暴露于HepG2和A172细胞(82FR-31NR细胞)的长期分级辐射中82天来分离出存活的CSC。 82FR-31NR细胞表现出CSC特性,例如CSC标记CD133和ABC转运蛋白(MDR1和BCRP1)的高表达,以及在移植到裸鼠后的高致瘤性。我们分离出的CSC的优势在于它们可以在与亲代细胞相同的生长培养基中增殖而不会丧失CSC特性。因此,我们可以分析非干细胞和CSC的DDR,而不会受到不同培养条件引起的任何影响。 82FR-31NR细胞通过激活AKT /细胞周期蛋白D1生存信号通路,对辐射诱导的DNA损伤和放射抗性进行了有效的DNA修复。相比之下,与分离的CSC相比,DNA损伤在亲代细胞照射后持续了很长时间。持久的DNA损伤在不激活AKT / cyclin D1途径的情况下诱导亲代细胞凋亡。因此,AKT抑制剂,API-2或细胞周期蛋白D1 siRNA对AKT /细胞周期蛋白D1途径的抑制作用导致有效DNA修复和82FR-31NR细胞放射增敏作用的丧失。此外,通过其siRNA或Cdk4抑制剂敲低Cdk4足以抑制CSC的放射抗性。在这项研究中,我们提出了一个新发现的有关AKT /细胞周期蛋白D1 / Cdk4途径的DDR,以响应CSC中的辐射。分馏RT和靶向AKT / cyclin D1 / Cdk4途径以根除CSC的试剂的组合将是有效的治疗方法。 2012 Macmillan Publishers Limited

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号